U.S. FDA approves Vanda's circadian rhythm drug Hetlioz
(Reuters) - Vanda Pharmaceuticals Inc said on Friday that U.S. health regulators have approved its experimental drug to regulate the internal body clocks of blind patients and help normalize sleep patterns.
The drug, Hetlioz, is designed to treat Non-24-Hour Sleep-Wake Disorder, or Non-24, a condition that is common among the totally blind, which can cause disrupted nighttime sleep patterns and excessive daytime sleepiness.
Vanda's shares rose 8.1 percent to $14.15 in afternoon trading after initially rising as high as $15.59 on the news.
- Missing jet may have strayed toward Andaman Sea: Malaysian air force |
- Malaysia military source says missing jet veered to west |
- Ukraine appeals to the West as Crimea turns to Russia |
- Toddler found with heroin at New Jersey daycare center
- Search under way at New York building collapse, trains halted